Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Completed · Phase 3
Conditions studied: Atypical Hemolytic Uremic Syndrome (aHUS)
In brief
The purpose of the study is to assess the safety and efficacy of ravulizumab to control disease activity in adolescent and adult participants with aHUS who had not previously used a complement inhibitor.
Key facts
- Study ID
- NCT02949128
- Run by
- Alexion Pharmaceuticals, Inc.
- People needed
- 58
- Starts
- 2017-01-11
- Expected to finish
- 2023-01-24
- Last updated by the study team
- 2024-02-20
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male or female ≥ 12 years of age and weighing ≥ 40 kg at the time of consent.
- Evidence of thrombotic microangiopathy, including low platelet count, hemolysis (breaking of red blood cells inside of blood vessels), and decreased kidney function.
- Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study drug. Participants who received a meningococcal vaccine less than 2 weeks before initiating ravulizumab treatment must have received treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Participants who had not been vaccinated prior to initiating ravulizumab treatment should have received prophylactic antibiotics prior to and for at least 2 weeks after meningococcal vaccination. Participants < 18 years of age must have been vaccinated against haemophilus influenzae type b and streptococcus pneumoniae according to national and local vaccination schedule guidelines.
- Female participants of childbearing potential and male participants with female partners of childbearing potential had to use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ravulizumab.
You may not qualify if…
- A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 deficiency (activity < 5%).
- Shiga toxin-related hemolytic uremic syndrome.
- Positive direct Coombs test.
- Pregnancy or breastfeeding.
- Identified drug exposure-related hemolytic uremic syndrome (HUS).
- Bone marrow transplant/hematopoietic stem cell transplant within last 6 months prior to start of Screening.
- HUS related to known genetic defects of cobalamin C metabolism.
- Systemic sclerosis (scleroderma), systemic lupus erythematosus, or antiphospholipid antibody positivity or syndrome.
- Chronic dialysis (defined as dialysis on a regular basis as renal replacement therapy for end-stage kidney disease).
Where it is running
- Clinical Trial Site — Fort Wayne, Indiana, United States
- Clinical Trial Site — Fort Wayne, Indiana, United States
- Clinical Trial Site — Durham, North Carolina, United States
- Clinical Trial Site — Winston-Salem, North Carolina, United States
- Clinical Trial Site — Columbus, Ohio, United States
- Clinical Trial Site — Clayton, Australia
- Clinical Trial Site — Geelong, Australia
- Clinical Trial Site — Parkville, Australia
- Clinical Trial Site — Vienna, Austria
- Clinical Trial Site — Brussels, Belgium
- Clinical Trial Site — London, Canada
- Clinical Trial Site — Bordeaux, France
- Clinical Trial Site — Clermont-Ferrand, France
- Clinical Trial Site — Lille, France
- Clinical Trial Site — Montpellier, France
- Clinical Trial Site — Nice, France
- Clinical Trial Site — Paris, France
- Clinical Trial Site — Aachen, Germany
- Clinical Trial Site — Essen, Germany
- Clinical Trial Site — Hanover, Germany
- Clinical Trial Site — München, Germany
- Clinical Trial Site — Tübingen, Germany
- Clinical Trial Site — Bologna, Italy
- Clinical Trial Site — Florence, Italy
- Clinical Trial Site — Saitama, Japan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.